Compare Nike Inc (NKE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Nike Inc trades at $34.85 (market cap $51.60B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.5× Nike Inc's market cap, and Nike Inc pays a 4.72% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nike Inc for 155 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| NKE | VRTX | |
|---|---|---|
Market Cap | $51.60B | $127.55B |
Volume | 43,506,062 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.68 | $557.96 |
52-Week Low | $33.87 | $407.37 |
Typical Hold Time | 155 Days | 120 Days |
Enterprise Value | $54.30B | $121.68B |
Dividend Yield | 4.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $34.74, up 0.38% on the day, amid a bearish technical signal and mixed earnings history. The stock shows strong profitability with a 43.07% gross margin and 21.56% ROE, but revenue declined to $46.31B in 2025. Recent news highlights challenges in China and EMEA, while analysts maintain a $36.98 consensus target.
Nike's outlook hinges on executing its turnaround strategy to revive growth. Investment opportunities include brand strength and digital initiatives, but risks involve sluggish demand, margin pressure, and intense competition. The stock's valuation appears reasonable with a P/E of 16.44, yet near-term headwinds warrant caution.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
